APRE Aprea Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1781983 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-8.5%
TTM EPS YoY73.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-62.8%
ROA-53.2%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets12.1%
Debt / equity0.00x
Current ratio9.67x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $7.04M | $9.36M | $7.63M | $16.40M | $23.90M |
| SG&A expense | $6.48M | $6.46M | $8.43M | $20.97M | $13.55M |
| Operating income | -$13.23M | -$14.32M | -$15.47M | -$113.39M | -$37.45M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$12.60M | -$12.96M | -$14.29M | -$112.66M | -$37.13M |
| EBITDA | -$13.21M | -$14.30M | -$15.46M | -$113.39M | -$37.43M |
| EPS (basic) | -1.93 | -2.35 | -3.95 | -67.99 | -34.88 |
| EPS (diluted) | -1.93 | -2.35 | -3.95 | -67.99 | -34.88 |
| Weighted avg. shares (diluted) | 6.54M | 5.51M | 3.62M | 1.66M | 1.06M |
| Balance sheet | |||||
| Cash & equivalents | $14.60M | $22.89M | $21.65M | $28.79M | $53.08M |
| Current assets | $15.56M | $23.58M | $22.52M | $30.15M | $56.58M |
| PP&E, net | $59,807 | $81,522 | $88,362 | $2,321 | $23,870 |
| Total assets | $15.93M | $23.98M | $22.65M | $30.16M | $56.82M |
| Current liabilities | $2.76M | $3.36M | $4.39M | $3.20M | $7.32M |
| Total liabilities | $3.49M | $4.67M | $5.70M | $3.20M | $7.32M |
| Shareholders' equity | $12.44M | $19.31M | $16.95M | $25.64M | $49.51M |
| Shares outstanding | 8.19M | 5.48M | 3.74M | 2.66M | 1.09M |
| Cash flow statement | |||||
| Operating cash flow | -$12.89M | -$13.56M | -$12.18M | -$25.01M | -$37.69M |
| Capital expenditure | — | $15,478 | $93,093 | — | — |
| Free cash flow | — | -$13.57M | -$12.27M | — | — |
| Investing cash flow | — | -$15,478 | -$93,093 | — | — |
| Financing cash flow | $4.64M | $14.82M | $5.14M | $682,973 | $1.75M |
| Depreciation & amortization | $21,715 | $22,318 | $7,052 | $4,403 | $12,829 |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.